Solid Tumors Clinical Trials in Los Angeles, California

11 studies are recruiting for solid tumors in Los Angeles, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

   The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-u…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   UCLA - Hematology/Oncology - Administrative Office ( Site 0009), Los Angeles, California

   Locations

   782 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT03486873 on ClinicalTrials.gov

2. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

   The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Investigative Site US027, Los Angeles, California

   Locations

   229 in total

   Run by

   Incyte Corporation

   See if you can join NCT07522073 on ClinicalTrials.gov

3. A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)

   This study is open to adults with different types of advanced cancer. People can take part if previous treatment was not successful, or no treatment exists. The purpose of this study is to find the highest dose of a medicine called BI 1703880 that people with advanced cancer can tolerate when taken…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Valkyrie Clinical Trials, Los Angeles, California

   Locations

   13 in total

   Run by

   Boehringer Ingelheim

   See if you can join NCT05471856 on ClinicalTrials.gov

4. Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

   A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   USC Norris Comprehensive Cancer Center, Los Angeles, California

   Locations

   16 in total

   Run by

   Tyra Biosciences, Inc

   See if you can join NCT06915753 on ClinicalTrials.gov

5. A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

   To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Angeles Clinic and Research Institute, Los Angeles, California

   Locations

   39 in total

   Run by

   Incyte Corporation

   See if you can join NCT05836324 on ClinicalTrials.gov

6. Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors

   The purpose of this study is to evaluate the safety and tolerability of investigational study drug ZL-6201 for treating sarcoma and solid tumors cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Zai Lab Site 02003, Los Angeles, California

   Locations

   8 in total

   Run by

   Zai Lab (Shanghai) Co., Ltd.

   See if you can join NCT07374848 on ClinicalTrials.gov

7. DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

   A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors

   Stage

   Phase 2

   Ages

   18 and older

   Site

   USA06-0, Los Angeles, California

   Locations

   37 in total

   Run by

   DualityBio Inc.

   See if you can join NCT06953089 on ClinicalTrials.gov

8. QTX3034 in Patients With KRAS G12D Mutation

   Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCLA Hematology/Oncology, Los Angeles, California

   Locations

   14 in total

   Run by

   Quanta Therapeutics

   See if you can join NCT06227377 on ClinicalTrials.gov

9. S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

   The primary objective of Part A is to evaluate the safety and tolerability of S-531011 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of S-531011 with or without pembrolizumab. The primary objective of Parts B and C is to evaluate the antitumor activity of …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Angeles Clinic and Research Center, Los Angeles, California

   Locations

   8 in total

   Run by

   Shionogi

   See if you can join NCT05101070 on ClinicalTrials.gov

10. A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors

    The primary purpose of the study is to characterize the safety and tolerability of XB371. The dose-escalation cohorts and Part B of the expansion cohorts are non-randomized. Part A of the expansion cohorts is randomized.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Exelixis Clinical Site #9, Los Angeles, California

    Locations

    9 in total

    Run by

    Exelixis

    See if you can join NCT07123103 on ClinicalTrials.gov

11. APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

    To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring w…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California

    Locations

    35 in total

    Run by

    Apollomics Inc.

    See if you can join NCT03175224 on ClinicalTrials.gov